

FORM 3

**UNITED STATES SECURITIES AND EXCHANGE
COMMISSION**

Washington, D.C. 20549

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF
SECURITIES**

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>ABG WTT-MedAvail Ltd</u> <hr/> (Last) (First) (Middle) UNIT 3002-3004, 30TH FLOOR GLOUCESTER TOWER, THE LANDMARK, CENTRAL <hr/> (Street) HONG KONG K3 <hr/> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 11/18/2020	3. Issuer Name and Ticker or Trading Symbol <u>MedAvail Holdings, Inc.</u> [MDVL]	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	3,782,080	I	See footnotes ⁽¹⁾
Common Stock	2,835,090	I	See footnotes ⁽²⁾

**Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			

1. Name and Address of Reporting Person* <u>ABG WTT-MedAvail Ltd</u> <hr/> (Last) (First) (Middle) UNIT 3002-3004, 30TH FLOOR GLOUCESTER TOWER, THE LANDMARK, CENTRAL <hr/> (Street) HONG KONG K3 <hr/> (City) (State) (Zip)
1. Name and Address of Reporting Person* <u>Ally Bridge Group-WTT Global Life Science Capital Partners, L.P.</u> <hr/> (Last) (First) (Middle) UNIT 3002-3004, 30TH FLOOR GLOUCESTER TOWER, THE LANDMARK, CENTRAL <hr/> (City) (State) (Zip)

(Street) HONG KONG K3		
<hr/>		
(City)	(State)	(Zip)

1. Name and Address of Reporting Person*

[ABG-WTT Global Life Science Capital Partners GP, L.P.](#)

(Last) (First) (Middle)

UNIT 3002-3004, 30TH FLOOR

GLOUCESTER TOWER, THE LANDMARK,
CENTRAL

(Street)

HONG KONG K3

(City) (State) (Zip)

1. Name and Address of Reporting Person*

[ABG-WTT Global Life Science Capital Partners GP Ltd](#)

(Last) (First) (Middle)

UNIT 3002-3004, 30TH FLOOR

GLOUCESTER TOWER, THE LANDMARK,
CENTRAL

(Street)

HONG KONG K3

(City) (State) (Zip)

1. Name and Address of Reporting Person*

[ABG Management Ltd.](#)

(Last) (First) (Middle)

UNIT 3002-3004, 30TH FLOOR

GLOUCESTER TOWER, THE LANDMARK,
CENTRAL

(Street)

HONG KONG K3

(City) (State) (Zip)

1. Name and Address of Reporting Person*

[Yu Fan](#)

(Last) (First) (Middle)

UNIT 3002-3004, 30TH FLOOR

GLOUCESTER TOWER, THE LANDMARK,
CENTRAL

(Street)

HONG KONG K3

(City) (State) (Zip)

1. Name and Address of Reporting Person*

[Ally Bridge MedAlpha Master Fund L.P.](#)

(Last) (First) (Middle)

430 PARK AVENUE, 12TH FLOOR,		
<hr/>		
(Street)		
NEW YORK	NY	10022
<hr/>		
(City)	(State)	(Zip)

1. Name and Address of Reporting Person*		
Ally Bridge MedAlpha Management L.P.		
<hr/>		
(Last)	(First)	(Middle)
430 PARK AVENUE, 12TH FLOOR,		
<hr/>		
(Street)		
NEW YORK	NY	10022
<hr/>		
(City)	(State)	(Zip)

1. Name and Address of Reporting Person*		
Ally Bridge MedAlpha Management GP, LLC		
<hr/>		
(Last)	(First)	(Middle)
430 PARK AVENUE, 12TH FLOOR,		
<hr/>		
(Street)		
NEW YORK	NY	10022
<hr/>		
(City)	(State)	(Zip)

1. Name and Address of Reporting Person*		
Ally Bridge Group (NY) LLC		
<hr/>		
(Last)	(First)	(Middle)
430 PARK AVENUE, 12TH FLOOR,		
<hr/>		
(Street)		
NEW YORK	NY	10022
<hr/>		
(City)	(State)	(Zip)

Explanation of Responses:

1. These securities are held of record by ABG WTT-MedAvail Limited ("ABG WTT"). ABG WTT is wholly owned by Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. Voting and investment decisions with respect to any securities held of record by ABG WTT are made by the investment committee of ABG-WTT Global Life Science Capital Partners GP Limited, which is the general partner of ABG-WTT Global Life Science Capital Partners GP, L.P., which is the general partner of Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. As such, each of the foregoing entities may be deemed to share beneficial ownership of the shares held by ABG-WTT. Each of them disclaims any such beneficial ownership.

2. These securities are held of record by Ally Bridge MedAlpha Master Fund L.P. ("MedAlpha"). Mr. Fan Yu is the sole shareholder of ABG Management Ltd., which is the sole member of each of Ally Bridge MedAlpha Management GP, LLC and Ally Bridge Group (NY) LLC. Ally Bridge Group (NY) LLC and Ally Bridge MedAlpha Management L.P., acting through its general partner Ally Bridge MedAlpha Management GP, LLC, manage MedAlpha's investments. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the shares held of record by MedAlpha. Each of them disclaims any such beneficial ownership.

Remarks:

[Ally Bridge Group-WTT
Global Life Science
Capital Partners, L.P., By:
ABG-WTT Global Life
Science Capital Partners
GP, L.P., its general
partner, By: ABG-WTT
Global Life Science
Capital Partners GP
Limited, its general
partner, By: /s/ Fan Yu,
Director](#) 11/30/2020

[ABG-WTT Global Life
Science Capital Partners](#) 11/30/2020

<u>GP, L.P., By: ABG-WTT</u>	
<u>Global Life Science</u>	
<u>Capital Partners GP</u>	
<u>Limited, its general</u>	
<u>partner, By: /s/ Fan Yu,</u>	
<u>Director</u>	
<u>ABG-WTT Global Life</u>	
<u>Science Capital Partners</u>	
<u>GP Limited, By: /s/ Fan</u>	<u>11/30/2020</u>
<u>Yu, Director</u>	
<u>Ally Bridge MedAlpha</u>	
<u>Master Fund L.P., By: Ally</u>	
<u>Bridge MedAlpha General</u>	
<u>Partner L.P., its general</u>	
<u>partner, By: Ally Bridge</u>	<u>11/30/2020</u>
<u>MedAlpha GP, LLC, its</u>	
<u>general partner, By: /s/ Fan</u>	
<u>Yu, Manager</u>	
<u>Ally Bridge MedAlpha</u>	
<u>Management L.P., By:</u>	
<u>Ally Bridge MedAlpha</u>	
<u>Management GP, LLC, its</u>	
<u>general partner, By: ABG</u>	<u>11/30/2020</u>
<u>Management Ltd., its</u>	
<u>managing member, By: /s/</u>	
<u>Fan Yu, Director</u>	
<u>Ally Bridge MedAlpha</u>	
<u>Management GP, LLC,</u>	
<u>By: ABG Management</u>	<u>11/30/2020</u>
<u>Ltd., its managing</u>	
<u>member, By: /s/ Fan Yu,</u>	
<u>Director</u>	
<u>Ally Bridge Group (NY)</u>	
<u>LLC, By: ABG</u>	
<u>Management Ltd., its</u>	<u>11/30/2020</u>
<u>managing member, By: /s/</u>	
<u>Fan Yu, Director</u>	
<u>ABG Management Ltd.,</u>	<u>11/30/2020</u>
<u>By: /s/ Fan Yu, Director</u>	
<u>ABG WTT-MedAvail</u>	
<u>Limited, By: /s/ Charles</u>	<u>11/30/2020</u>
<u>Chon, Director</u>	
<u>/s/ Fan Yu</u>	<u>11/30/2020</u>
** Signature of Reporting	Date
Person	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.